IngbarDH, NairS.Oxygen transport in the critically ill patient. Appl Cardiopulm Physiol1989;3:97–120.
3.
KahnRC, ZaroulisC, GoetzW, HowlandWS. Hemodynamic oxygen transport and 2,3-diphosphoglycerate changes after transfusion of patients in acute respiratory failure. Intensive Care Med1986;12:22–25.
4.
WinslowRM. Optimal hematologic variables for oxygen transport, including P50, hemoglobin cooperativity, hematocrit, acid-base status, and cardiac function. Biomater Artif Cells Artif Org1988;16:149–171.
5.
GeyerRP. Fluorocarbon-polyol artificial blood substitutes. N Engl J Med1973;289:1077–1082.
6.
ClarkLC, GollanF.Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science1966;152:1755–1756.
7.
GeyerRP. "Bloodless" rats through the use of artificial blood substitutes. Fed Proc1975;34:1499–1505.
8.
TremperKK, CullenBF. U.S. clinical studies of the treatment of anemia with Fluosol-DA 20%. Artif Organs1984;8:19–24.
9.
TremperKK, AndersonST. Perfluorochemical emulsion oxygen transport fluids: A clinical review. Ann Rev Med1985;309:313.
10.
MitsunoT, OhyanagiH.Present status of clinical studies of Fluosol-DA (20%) in Japan. Intern Anesthesiol Clin1985;23:169–184.
11.
TremperKK, FriedmanAE, LevineEM, LapinR, CamarilloD.The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA. N Engl J Med1982;307:277–283.
FormanMB, BinghamS, KopelmanHA, . Reduction of infarct size with intracoronary perfluorochemical in a canine preparation of reperfusion. Circulation1985;71:1060–1068.
17.
ClemanM, JaffeeCC, WohlgelernterD.Prevention of ischemia during percutaneous transluminal coronary angioplasty by transcatheter infusion of oxygenated Fluosol DA 20%. Circulation1986;74:555–562.
18.
JaffeCC, WohlgelernterD, CabinH, . Preservation of left ventricular ejection fraction during percutaneous transluminal coronary angioplasty by distal transcatheter coronary perfusion of oxygenated Fluosol DA 20%. Am Heart J1988;115:1156–1164.
19.
PeerlessSJ, IshikawaR, HunterIG, PeerlessMJ. Protective effect of Fluosol-DA in acute cerebral ischemia. Stroke1981;12:558–563.
20.
NagasawaS, HandaH, YonekawaY, OdaY, TsudaY, YokoyamaK.Effects of a transfusion with a blood substitute (Fluosol-DA, 20%). Part II: Human cerebral blood flow. Neurol Res1983;5:19–30.
21.
ReindorfCA, Kurantsin-MillsJ, AlloteyJB, CastroO.Perfluorocarbon compounds: Effects on the rheological properties of sickle eythrocytes in vitro. Am J Hematol1985;19:229–236.
22.
BandoK, TeramotoS, TagoM, . Oxygenated perfluorocarbon, recombinant human superoxide dismutase, and catalase ameliorate free radical induced myocardial injury during heart preservation and transplantation. J Thorac Cardiovasc Surg1988;96:930–938.
23.
RockwellS.Perfluorochemical emulsions as adjuncts to radiotherapy. Biomater Artif Cells Artif Organs1988;16:519–532.
24.
MartinDF, PorterEA, RockwellS, FischerJJ. Enhancement of tumor radiation response by the combination of perfluorochemical emulsion and hyperbaric oxygen. Int J Radiat Oncol Biol Phys1987;13:747–751.
25.
RoseC, LustigR, McIntoshN, TeicherB.Clinical trial of Fluosol DA 20% in advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys1986;12:1325–1327.
26.
TeicherBA, McIntoshNL, RoseCM. Effect of various oxygenation conditions and Fluosol DA on cancer chemotherapeutic agents. Biomater Artif Cells Artif Organs1988;16:533–546.
27.
KuwamuraK, KokunaiT, TamakiN, MatsumotoS.Synergistic effect of perfluorochemicals on BCNU chemotherapy. J Neurosurg1982;57:467–471.
28.
TeicherBA, KazoJS, MerrillWW, FildermanAE, RoseCM. Effect of Fluosol-DA 20 on the antitumor activity and pulmonary toxicity of bleomycin. Cancer Chemother Pharmacol1986;18:213–218.
29.
VercellottiGM, HammerschmidtDE, CraddockPR, JacobHS. Activation of plasma complement by perfluorocarbon artificial blood: Probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticosteroid prophylaxis. Blood1982;59:1299–1304.
30.
LaneTA, KrukonisV.Reduction in the toxicity of a component of an artificial blood substitute by supercritical fluid fractionation. Transfusion1988;28:375–378.
31.
WaxmanK, CheungCK, MasonGR. Hypotensive reaction after infusion of a perfluorochemical emulsion. Crit Care Med1984;12:609–610.
32.
TremperKK, VercellottiGM, HammerschmidtDE. Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%. Crit Care Med1984;12:428–431.
33.
PoliceAM, WaxmanK, TominagaG.Pulmonary complications after Fluosol administration to patients with life-threatening blood loss. Crit Care Med1985;13:96–98.
34.
LaneTA, LamkinGE. Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute. Blood1986;68:351–354.
35.
LaneTA, LamkinGE. Paralysis of phagocyte migration due to an artificial blood substitute. Blood1984;64:400–405.
36.
VirmaniR, FinkLM, GunterK, EnglishD.Effect of perfluorochemical blood substitutes on human neutrophil function. Transfusion1984;24:343–347.
37.
BucalaR, KawakamiM, CeramiA.Cytoxicity of a perfluorocarbon blood substitute to macrophages in vitro. Science1983;220:965–967.
38.
JancoRL, VirmaniR, MorrisPJ, GunterK.Perfluorochemical blood substitutes differentially alter human monocyte procoagulant generation and oxidative metabolism. Transfusion1985;25:578–582.
39.
LongDM, LongDC, MattreyRF, . An overview of perfluoroctylbromide application as a synthetic oxygen carrier and imaging agent for x-ray, ultrasound, and nuclear magnetic resonance. Biomater Artif Cells Artif Organs1988;16:411–420.
40.
BurganAR, HerrickWC, LongDM, LongDC. Acute and subacute toxicity of 100% PFOB emulsion. Biomater Artif Cells Artif Organs1988;16:681–682.
41.
GouldSA, SehgalLR, RosenAL, SehgalHL, MossGS. Red cell substitutes: An update. Ann Emerg Med1985;14:796–803.
KeipertPE, AdeniranAJ, KwongS, BeneschRE. Functional properties of a new crosslinked hemoglobin designed for use as a red cell substitute. Transfusion1989;29:768–773.
47.
GouldSA, RosenAL, SehgalLR, SehgalHL, RiceCL, MossGS. Red cell substitutes: Hemoglobin solution or fluorocarbon?J Trauma1982;22:736–740.
ValeriCR, ZaroulisCG, VecchioneJJ, . Therapeutic effectiveness and safety of outdated human red blood cells rejuvenated to improve oxygen transport function, frozen for about 1.5 years at 8°C, washed, and stored at 4°C for 24 hours prior to rapid infusion. Transfusion1980;20:263–276.
50.
RoparsC, TeisseireB, AvenardG, . Improved oxygen delivery to tissues and iron chelator transport through the use of lysed and resealed red blood cells: A new perspective on Cooley's anemia therapy. Ann NY Acad Sci1985;445:304–315.
51.
HuntCA, BurnetteRR, MacGregorRD, StrubgeAE. Synthesis and evaluation of a prototypal artificial red cell. Science1985;230:1165–1168.
52.
MillerIF, MayoralJ, DjordjevichL, KashaniA.Hemodynamic effects of exchange transfusions with liposome-encapsulated hemoglobin. Biomater Artif Cells Artif Organs1988;16:281–288.
53.
BartlettRH. A critical carol—Being an essay on anemia, suffocation, starvation, and other forms of intensive care, after the manner of Dickens. Chest1985;88:687–693.
